NO982044L - Sublingual og bukkal administrering av selegilin for behandling av bestemte selegilin-responderende sykdommer og tilstander - Google Patents

Sublingual og bukkal administrering av selegilin for behandling av bestemte selegilin-responderende sykdommer og tilstander

Info

Publication number
NO982044L
NO982044L NO982044A NO982044A NO982044L NO 982044 L NO982044 L NO 982044L NO 982044 A NO982044 A NO 982044A NO 982044 A NO982044 A NO 982044A NO 982044 L NO982044 L NO 982044L
Authority
NO
Norway
Prior art keywords
selegiline
conditions
responsive diseases
sublingual
treatment
Prior art date
Application number
NO982044A
Other languages
English (en)
Other versions
NO982044D0 (no
NO317855B1 (no
Inventor
Anthony R Disanto
Original Assignee
Somerset Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21725510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO982044(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Somerset Pharmaceuticals Inc filed Critical Somerset Pharmaceuticals Inc
Publication of NO982044D0 publication Critical patent/NO982044D0/no
Publication of NO982044L publication Critical patent/NO982044L/no
Publication of NO317855B1 publication Critical patent/NO317855B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
NO19982044A 1995-11-06 1998-05-05 Anvendelse av selegilin eller et farmasoytisk akseptabelt salt derav. NO317855B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US732595P 1995-11-06 1995-11-06
PCT/US1996/017745 WO1997017067A1 (en) 1995-11-06 1996-11-05 Sublingual and buccal administration of selegiline

Publications (3)

Publication Number Publication Date
NO982044D0 NO982044D0 (no) 1998-05-05
NO982044L true NO982044L (no) 1998-07-02
NO317855B1 NO317855B1 (no) 2004-12-20

Family

ID=21725510

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982044A NO317855B1 (no) 1995-11-06 1998-05-05 Anvendelse av selegilin eller et farmasoytisk akseptabelt salt derav.

Country Status (13)

Country Link
US (1) US6117912A (no)
EP (1) EP0866691B2 (no)
JP (1) JPH11504944A (no)
CN (1) CN1207675A (no)
AT (1) ATE219358T1 (no)
AU (1) AU707646B2 (no)
CA (1) CA2236368C (no)
DE (1) DE69621946T3 (no)
DK (1) DK0866691T4 (no)
ES (1) ES2180809T5 (no)
NO (1) NO317855B1 (no)
PT (1) PT866691E (no)
WO (1) WO1997017067A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106241A1 (en) * 1995-02-03 2005-05-19 Brewer Francesca M. Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors
BR9607057A (pt) † 1995-03-02 1998-06-09 Scherer Ltd R P Composições farmacêuticas compreendendo inibidores monoamina oxidase b
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US6576250B1 (en) 1998-03-27 2003-06-10 Cima Labs Inc. Pharmaceutical compositions for rectal and vaginal administration
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
DE19814257A1 (de) 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
AU2007203233B2 (en) * 1999-03-26 2010-02-25 Cima Labs Inc. Sublingual buccal effervescent
AU2004242477B2 (en) * 1999-03-26 2007-04-19 Cima Labs Inc. Sublingual buccal effervescent
GB0017952D0 (en) * 2000-07-22 2000-09-13 Univ Manchester Treatment of dyskinesia
US7619005B2 (en) 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
JP2004534724A (ja) * 2000-11-01 2004-11-18 センション，インコーポレイテッド 記憶固化を調節するための方法および組成物
US20030232890A1 (en) 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
EP1743631A3 (en) * 2000-11-01 2009-11-18 Cognition Pharmaceuticals LLC Use of an amphetamine composition for regulating memory consolidation
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
CA2474154A1 (en) * 2002-01-18 2003-07-24 Tatton Technologies, Llc. Methods for treating eye disorders
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
DE602004031462D1 (de) * 2003-12-31 2011-03-31 Cima Labs Inc Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
CA2549642C (en) * 2003-12-31 2012-10-30 Cima Labs Inc. Effervescent oral opiate dosage forms and methods of administering opiates
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
US20060264478A1 (en) * 2005-02-22 2006-11-23 Northwestern University Methods and compositions for modulating calcium channels
AU2006265113A1 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
CN103860503A (zh) * 2012-12-10 2014-06-18 天津市汉康医药生物技术有限公司 一种治疗帕金森病的缓释药物组合物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241809B1 (de) * 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US4885154A (en) * 1988-03-01 1989-12-05 Alza Corporation Method for reducing sensitization or irritation in transdermal drug delivery and means therefor
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5151449A (en) * 1990-08-31 1992-09-29 Deprenyl Animal Health, Inc. Use of L-deprenyl for retention of specific physiological functions
US5192808A (en) * 1990-08-31 1993-03-09 Deprenyl Animal Health, Inc. Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease)
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
BR9607057A (pt) * 1995-03-02 1998-06-09 Scherer Ltd R P Composições farmacêuticas compreendendo inibidores monoamina oxidase b

Also Published As

Publication number Publication date
CA2236368C (en) 2001-10-23
CA2236368A1 (en) 1997-05-15
DK0866691T3 (da) 2002-10-14
EP0866691A1 (en) 1998-09-30
AU707646B2 (en) 1999-07-15
EP0866691B1 (en) 2002-06-19
DK0866691T4 (da) 2005-06-06
DE69621946D1 (de) 2002-07-25
ES2180809T5 (es) 2005-06-16
WO1997017067A1 (en) 1997-05-15
CN1207675A (zh) 1999-02-10
PT866691E (pt) 2002-11-29
ATE219358T1 (de) 2002-07-15
DE69621946T2 (de) 2003-01-30
EP0866691B2 (en) 2005-01-26
JPH11504944A (ja) 1999-05-11
NO982044D0 (no) 1998-05-05
NO317855B1 (no) 2004-12-20
DE69621946T3 (de) 2005-05-25
US6117912A (en) 2000-09-12
AU7608096A (en) 1997-05-29
ES2180809T3 (es) 2003-02-16

Similar Documents

Publication Publication Date Title
NO982044L (no) Sublingual og bukkal administrering av selegilin for behandling av bestemte selegilin-responderende sykdommer og tilstander
EG20273A (en) Process for preparing of pyrazolopyrimidines and their use in the treatment of stress related and other diseases
WO2002002518A3 (en) Compounds to treat alzheimer's disease
DE69133516D1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE69502939D1 (de) Sublinguales oder bukkales arzneimittel
WO2002002520A8 (en) Compounds to treat alzheimer's disease
SE9503924D0 (sv) Novel opioid peptides
CA2029047A1 (en) Sustained release compositions for treating periodontal disease
ATE82294T1 (de) Therapeutische nukleoside.
RU94046141A (ru) Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция
HUP0003174A2 (hu) 20(S)-Kamptotecin glikokonjugátumai, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
PT1007040E (pt) Utilizacao de fanquinona no tratamento da doenca de alzheimer
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
ATE72120T1 (de) Verwendung von petasites-extrakten zur herstellung eines arzneimittels zur behandlung von gastrointestinalen erkrankungen.
EP0383481A3 (en) Anesthetic oral compositions
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
MX9710093A (es) Uso de aminas alilicas.
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона
ES2127133A1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.
SE9502877D0 (sv) Novel opioid peptides
GB2316406A (en) Free radical scavenger molecules

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees